Doctors without Borders/Médecins Sans Frontières (MSF) on Friday called for the removal of access to medicines provisions in the Trans-Pacific Partnership (TPP) trade deal, saying if not checked it could lock out a major chunk of the global population from receiving affordable medicines. 24 July 2015
Indian pharma companies may finally be looking at a better rate of clearances from the US Food and Drug Administration as the third year of GDUFA (Generic Drug User Fee Amendment of 2012) draws to a close. 22 July 2015
Synthetic biology specialist Intrexon Corp has appointed Jack Bobo as senior vice president, chief communications officer, Samuel Broder as senior vice president, head of health, and Joel Liffman as senior vice president, finance. 22 July 2015
US biotech major Biogen announced on Friday that head of R&D Douglas Williams will leave the company at the end of July to become chief executive of an as-yet unnamed start-up biotechnology company. 11 July 2015
Waypoint Capital, the business enterprise for investments associated with the Bertarelli family, has named Christopher Viehbacher as the managing partner of its US-based Gurnet Point Capital (GPC) fund. 24 June 2015
American pharma company Pozen has appointed Mark Glickman as chief commercial officer, Eric Trachtenberg as deputy general counsel, and Jennifer Armstrong as executive vice president of human resources and administration. 22 June 2015
Briggs Morrison, former vice president global medicines development and chief medical officer at AstraZeneca, is joining privately-held oncology company Syndax Pharmaceuticals as chief executive officer. 16 June 2015
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024